fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Fenofibrate

All products: general benefit

AA-Feno-Super · DIN 02246860 · 160 mg · tablet

General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
AA-Feno-Super · DIN 02246860 Manufacturer: A A Pharma Inc.; listing date 2006-06-14 Health Canada: Marketed since 2021-09-24 · brand AA-FENO-SUPER · ATC C10AB05 FENOFIBRATE · form Tablet · route Oral · ingredients FENOFIBRATE 160 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

AA-Feno-Super: Formulary list price $1.00 per unit (the source does not state the unit; exact figure $1.0022). What the ministry pays, not the patient.

Ministry pays: $1.0022 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02246860)

Source record
DIN 02246860: AA-Feno-Super Raw flags: chronicUseMed=Y, sec3=Y Item: 240600043; group id 303; item number 0661; lccId None; manufacturer id AAP Source form: Tab; strength: 160mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.0022; ministry $1.0022 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02246860 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71083
Interchangeable products
Lipidil Supra · DIN 02241602 · $1.0022
Shortage status: resolved shortage (ended September 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246860
Shortage record checked October 6, 2026

Other products in the same Health Canada class (C10A, C10AB): coverage varies; not interchangeable

  • Bezafibrate (Bezalip): general benefit
  • Gemfibrozil (Lopid): general benefit, not a benefit
  • Clofibrate (Atromid-S): not a benefit
  • Atorvastatin (Lipitor): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, not a benefit
  • Colesevelam (Lodalis): general benefit, listing status unconfirmed

9 more in the class list below

Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:06 Antilipemic Drugs

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

CLOFIBRATE

· 2 products · Listed, not a benefit · strengths: 500mg · Cap

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 84 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE FENOFIBRATE (fenofibrate, non-micronized formulation) and AA-FENO-MICRO (fenofibrate, micronized formulation) are indicated as an adjunct to diet and other therapeutic measures for: Page 3 of 37 1) Treatment of patients with hypercholesterolemia, Fredrickson classification Types IIa and IIb mixed hyperlipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol). 2) Treatment of adult patients with very high serum triglyceride levels, Fredrickson classification Type IV and Type V hyperlipidemias, who are at a high risk of sequelae and complications (i.e., pancreatitis) from their hyperlipidemia. FENOFIBRATE and AA-FENO-MICRO alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and Type IV hyperlipoproteinemia. Initial therapy for hyperlipidemia should include a specific diet (at least equivalent to the American Heart Association (AHA) Step I diet), weight reduction, and… https://pdf.hres.ca/dpd_pm/00053567.PDF PM date: not printed or not captured Source product: AA-FENO-MICRO; DIN 02239864; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.